Pompe Program Update

Category: Archive
December 3, 2009

Genzyme would like to provide an update to the US Pompe community about the status of the Alglucosidase Alfa Temporary Access Program (ATAP) and the application for Lumizyme™ (alglucosidase alfa) approval in the United States.

In a press release dated December 3, 2009, it was announced that Genzyme will reopen enrollment in ATAP to provide access to treatment for severely affected adults with Pompe disease prior to commercial approval of Lumizyme. Enrollment in the program will be available at currently active ATAP study sites to patients who meet the eligibility criteria. Please speak to your physician about ATAP or contact Genzyme Medical Information at 800-745-4447, option 2 for more information.

To read the full Program Update, please click here (PDF, 15 kB).

Back to news articles